A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Efforts to reduce stroke in patients with atrial fibrillation (AF) have focused on increasing physician adherence to oral anticoagulant (OAC) guidelines; however, the high early discontinuation rate of vitamin K antagonists (VKAs) is a limitation. Although non-VKA OACs (NOACs) are more convenient to administer than warfarin, their lack of monitoring may predispose patients to nonpersistence. We compared the persistence of NOAC and VKA treatment for AF in real-world practice. Methods: In a prospective observational registry (COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF] registry), 7,013 patients with nonvalvular AF (mean age 67.2 ± 10.9 years, women 36.4%) were consecutively enrolled between June 2016 and June 2017 from 10 tertiary hospitals in Korea. This study included 3,381 patients who started OAC 30 days before enrollment (maintenance group) and 572 patients who newly started OAC (new-starter group). The persistence rate of OAC was evaluated. Results: In the maintenance group, persistence to OAC declined during 6 months, to 88.3% for VKA and 95.5% for NOAC (p < 0.0001). However, the persistence rate was not different among NOACs. In the new-starter group, persistence to OAC declined during 6 months, to 78.9% for VKA and 92.1% for NOAC (p < 0.0001). The persistence rate was lower for rivaroxaban (83.7%) than apixaban (94.6%) and edoxaban (94.1%, p < 0.001). In the new-starter group, diabetes, valve disease, and cancer were related to nonpersistence of OAC. Conclusions: Nonpersistence was significantly lower with NOAC than VKA in both the maintenance and new-starter groups. In only the new-starter group, apixaban or edoxaban showed higher persistence rates than rivaroxaban.
Abstract
Background/Aims: Efforts to reduce stroke in patients with atrial fibrillation (AF) have focused on increasing physician adherence to oral anticoagulant (OAC) guidelines; however, the high early discontinuation rate of vitamin K antagonists (VKAs) is a limitation. Although non-VKA OACs (NOACs) are more convenient to administer than warfarin, their lack of monitoring may predispose patients to nonpersistence. We compared the persistence of NOAC and VKA treatment for AF in real-world practice. Methods: In a prospective observational registry (COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF] registry), 7,013 patients with nonvalvular AF (mean age 67.2 ± 10.9 years, women 36.4%) were consecutively enrolled between June 2016 and June 2017 from 10 tertiary hospitals in Korea. This study included 3,381 patients who started OAC 30 days before enrollment (maintenance group) and 572 patients who newly started OAC (new-starter group). The persistence rate of OAC was evaluated. Results: In the maintenance group, persistence to OAC declined during 6 months, to 88.3% for VKA and 95.5% for NOAC (p < 0.0001). However, the persistence rate was not different among NOACs. In the new-starter group, persistence to OAC declined during 6 months, to 78.9% for VKA and 92.1% for NOAC (p < 0.0001). The persistence rate was lower for rivaroxaban (83.7%) than apixaban (94.6%) and edoxaban (94.1%, p < 0.001). In the new-starter group, diabetes, valve disease, and cancer were related to nonpersistence of OAC. Conclusions: Nonpersistence was significantly lower with NOAC than VKA in both the maintenance and new-starter groups. In only the new-starter group, apixaban or edoxaban showed higher persistence rates than rivaroxaban.
참고문헌 (35)
- 이한철, "The Trends of Atrial Fibrillation-Related Hospital Visit and Cost, Treatment Pattern and Mortality in Korea: 10-Year Nationwide Sample Cohort Data", Korean Circulation Journal, 47(1), pp.56~64 (2017), 대한심장학회
- January CT, "2014 AHA", ACC, American Heart Association Task Force on practice guidelines and the Heart Rhythm Society, pp.Circulation, 2014[DOI]
- , vascular disease, age 65-74, female)for stroke in Asian patients with atrial fibrillation : a Korean nationwide sample cohort study, "Stroke", 2017, 1524~1530
- Hart RG, "Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
- Camm AJ, "2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association", Eur Heart J, 33, pp.2719~2747 (2012)
- January CT, "2014 AHA", ACC, American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, pp.J Am Coll Cardiol, 2014[DOI]
- You JJ, "Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines", Chest, 141(2 Suppl), pp.e531S~e575S (2012)
- Nelson WW, "Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation", Curr Med Res Opin, 30, pp.2461~2469 (2014)
- Shore S, "Site-level variation in and practices associated with dabigatran adherence", JAMA, 313, pp.1443~1450 (2015)
- Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
- Tsai K, "Adherence, persistence, and switching patterns of dabigatran etexilate", Am J Manag Care, 19, pp.e325~e332 (2013)
- Michel J, "Dabigatran for anticoagulation in atrial fibrillation : early clinical experience in a hospital population and comparison to trial data", Heart Lung Circ, 22, pp.50~55 (2013)
- Zalesak M, "Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin", Circ Cardiovasc Qual Outcomes, 6, pp.567~574 (2013)
- Shore S, "Adherence to dabigatran therapy and longitudinal patient outcomes : insights from the veterans health administration", Am Heart J, 167, pp.810~817 (2014)
- Laliberte F, "Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients", Curr Med Res Opin, 30, pp.1317~1325 (2014)
- Witt DM, "Approaches to optimal dosing of vitamin K antagonists", Semin Thromb Hemost, 38, pp.667~672 (2012)
- Patel MR, "Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)", J Am Coll Cardiol, 61, pp.651~658 (2013)
- Beyer-Westendorf J, "Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry", Europace, 17, pp.530~538 (2015)
- Gorst-Rasmussen A, "Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study", J Thromb Haemost, 13, pp.495~504 (2015)
- Forslund T, "Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation", Eur J Clin Pharmacol, 72, pp.329~338 (2016)
- Yao X, "Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation", J Am Heart Assoc, 5, pp.e003074~ (2016)
- Fang MC, "Warfarin discontinuation after starting warfarin for atrial fibrillation", Circ Cardiovasc Qual Outcomes, 3, pp.624~631 (2010)
- Gomes T, "Persistence with therapy among patients treated with warfarin for atrial fibrillation", Arch Intern Med, 172, pp.1687~1689 (2012)
- Jackevicius CA, "Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation", Heart, 103, pp.1331~1338 (2017)
- Johnson ME, "Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation : a cohort study in UK primary care", BMJ Open, 6, pp.e011471~ (2016)
- Collings SL, "Oral anticoagulant persistence in patients with non-valvular atrial fibrillation : a cohort study using primary care data in Germany", PLoS One, 12, pp.e0185642~ (2017)
- Rubboli A, "Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants : does the number of pills per day matter", Curr Med Res Opin, 31, pp.1845~1847 (2015)
- Claxton AJ, "A systematic review of the associations between dose regimens and medication compliance", Clin Ther, 23, pp.1296~1310 (2001)
- Beyer-Westendorf J, "Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation", Europace, 18, pp.1150~1157 (2016)
- Shiga T, "Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation : a single-center observational study", J Arrhythm, 31, pp.339~344 (2015)
- Lane DA, "Patient’s values and preferences for stroke prevention in atrial fibrillation : balancing stroke and bleeding risk with oral anticoagulation", Thromb Haemost, 111, pp.381~383 (2014)
- Lahaye S, "Evaluation of patients’attitudes towards stroke prevention and bleeding risk in atrial fibrillation", Thromb Haemost, 111, pp.465~473 (2014)